EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses

Isabelle Xavier-de-Britto, Natalia Cristina Gomes-da-Silva, Luciana Magalhães Rebelo Alencar, Eduardo Ricci-Junior, Pierre B A Fechine, Amanda Dos Santos Cavalcanti, Alessandra Cristina Chagas Valim, Jamila Alessandra Perini, Victor Branco de Sousa, Severino Alves Júnior, Daniel Escorsim Machado, Ralph Santos-Oliveira

European Journal of Pharmaceutics and Biopharmaceutics · 2026-11 · 228 · 115237

DOI: 10.1016/j.ejpb.2026.115237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-11. Verfasst von Isabelle Xavier-de-Britto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de…. Hauptthemen laut MEDLINE: Poloxamer, Endometriosis, Nanoparticles. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by ectopic endometrial-like glands and stroma, persistent pelvic inflammation, pain, infertility, and frequent recurrence. The limited availability of nonhormonal and lesion-directed therapies supports the investigation of alternative pharmacological mechanisms and regional drug-delivery strategies. Arimoclomol is a co-inducer of the endogenous heat-shock response with the capacity to amplify stress-dependent proteostasis, whereas Pluronic F127 is an amphiphilic PEO-PPO-PEO copolymer that forms drug-associated micellar assemblies in aqueous media. This exploratory study evaluated the physicochemical properties, in vitro release profile, and early biological response to arimoclomol-loaded Pluronic F127 nanomicelles in an autologous-transplantation rat model of endometriosis. The formulation was prepared by dispersing 30 mg of arimoclomol in 2 mL of Pluronic F127 at 20% (w/v), followed by stirring and ultrasonication under cooling. Because no centrifugation, filtration, dialysis, lyophilization, or other drug-removal step was applied after incorporation, the nominal process loading efficiency was 100%, based on formulation mass balance. The corresponding theoretical drug content was 6.98% w/w of total formulation solids and 7.5% w/w relative to the polymer mass. Drug-polymer association was supported by scanning electron microscopy coupled to energy-dispersive X-ray spectroscopy, Raman spectroscopy, and UV-Vis spectroscopy. In vitro dialysis at 37 °C showed a rapid increase in acceptor-medium arimoclomol concentration, reaching 14.33 ± 0.18 µg/mL at 2 h, followed by a progressive decline, with arimoclomol remaining detectable at 72 h (2.76 ± 0.04 µg/mL). Endometriosis was induced in ten female Wistar rats. On day 16, animals received a single intraperitoneal administration of arimoclomol-loaded nanomicelles (n = 4), empty nanomicelles (n = 3), or free arimoclomol (n = 3). The arimoclomol dose was 3 mg/animal, equivalent to approximately 14.7-16.8 mg/kg according to the recorded body-weight range. Twenty-four hours after treatment, representative lesions from the loaded-nanomicelle group appeared smaller macroscopically and showed mildly atrophic glands, stromal disorganization, and less prominent inflammatory infiltration than representative lesions from the empty-carrier and free-drug groups. All clinical welfare scores remained zero, and no overt short-term intolerance was observed. These findings demonstrate nominal quantitative drug retention based on process mass balance, a biphasic in vitro release pattern, and an early treatment-associated morphological and histological response. These preliminary findings require confirmation in larger, blinded, power-calculated studies with quantitative lesion endpoints, mechanistic biomarkers, lesion-specific pharmacokinetics, and longitudinal safety assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PoloxamerEndometriosisNanoparticlesAnimalsFemaleMicellesRatsDrug LiberationDrug CarriersRats, WistarPolyethylene GlycolsDisease Models, AnimalDrug Delivery Systems

Stichwörter der Autor:innen

ArimoclomolEndometriosisHeat-shock responseIn vitro releaseIntraperitoneal therapyNanomicellesPluronic F127

Substanzen

PoloxamerMicellesDrug CarriersPolyethylene Glycols

Autor:innen und Institutionen

  • Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, RJ 21941906, Brazil.
  • Federal University of Maranhão, Department of Physics, Biophysics Laboratory, Campus Bacanga, São Luís, MA 65080-805, Brazil.
  • LADEG, Laboratory of Pharmaceutical Nanotechnology, Faculty of Pharmacy, DEFARMED, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Group of Chemistry of Advanced Materials (GQMat), Department of Analytical Chemistry and Physical-Chemistry, Federal University of Ceará, Fortaleza, CE 451-970, Brazil.
  • Research Division, National Institute of Traumatology and Orthopedics, Rio de Janeiro 20940-070, Brazil; Research Laboratory of Pharmaceutical Science (LAPESF), Rio de Janeiro State University (UERJ), Av. Manuel Caldeir…
  • Research Laboratory of Pharmaceutical Science (LAPESF), Rio de Janeiro State University (UERJ), Av. Manuel Caldeira de Alvarenga, 1203, Campo Grande, Rio de Janeiro, RJ 23070-200, Brazil.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Xavier-de-Britto, I., Gomes-da-Silva, N. C., Alencar, L. M. R., Ricci-Junior, E., Fechine, P. B. A., Cavalcanti, A. D. S., Valim, A. C. C., Perini, J. A., de Sousa, V. B., Júnior, S. A., Machado, D. E., & Santos-Oliveira, R. (2026). Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses. European Journal of Pharmaceutics and Biopharmaceutics, 228, 115237. https://doi.org/10.1016/j.ejpb.2026.115237

Vancouver

Xavier-de-Britto I, Gomes-da-Silva NC, Alencar LMR, Ricci-Junior E, Fechine PBA, Cavalcanti ADS, et al. Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses. European Journal of Pharmaceutics and Biopharmaceutics. 2026;228:115237. doi:10.1016/j.ejpb.2026.115237

BibTeX
@article{XavierdeBritto2026,
  author = {Xavier-de-Britto, Isabelle and Gomes-da-Silva, Natalia Cristina and Alencar, Luciana Magalhães Rebelo and Ricci-Junior, Eduardo and Fechine, Pierre B A and Cavalcanti, Amanda Dos Santos and Valim, Alessandra Cristina Chagas and Perini, Jamila Alessandra and de Sousa, Victor Branco and Júnior, Severino Alves and Machado, Daniel Escorsim and Santos-Oliveira, Ralph},
  title = {Arimoclomol-loaded Pluronic F127 nanomicelles in experimental endometriosis: drug incorporation, in vitro release, and early morphological and histological responses},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  volume = {228},
  pages = {115237},
  doi = {10.1016/j.ejpb.2026.115237}
}
Kostenlos starten →